ATE539741T1 - Sphingolipide bei der behandlung und prävention von hepatischer steatose - Google Patents

Sphingolipide bei der behandlung und prävention von hepatischer steatose

Info

Publication number
ATE539741T1
ATE539741T1 AT05813546T AT05813546T ATE539741T1 AT E539741 T1 ATE539741 T1 AT E539741T1 AT 05813546 T AT05813546 T AT 05813546T AT 05813546 T AT05813546 T AT 05813546T AT E539741 T1 ATE539741 T1 AT E539741T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
sphingolipids
hepatic steatosis
sphingolipid
Prior art date
Application number
AT05813546T
Other languages
English (en)
Inventor
Willem Ferdinand Nieuwenhuizen
Aloysius Maria Havekes
Josephus Jan Emeis
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04078265A external-priority patent/EP1661562A1/de
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE539741T1 publication Critical patent/ATE539741T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05813546T 2004-11-30 2005-11-25 Sphingolipide bei der behandlung und prävention von hepatischer steatose ATE539741T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04078265A EP1661562A1 (de) 2004-11-30 2004-11-30 Verwendung von Sphingolipiden zur Behandlung und Vorbeugung von Steatose
EP05075856 2005-04-12
EP05077029 2005-09-06
PCT/NL2005/000813 WO2006059897A1 (en) 2004-11-30 2005-11-25 Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae

Publications (1)

Publication Number Publication Date
ATE539741T1 true ATE539741T1 (de) 2012-01-15

Family

ID=35744899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05813546T ATE539741T1 (de) 2004-11-30 2005-11-25 Sphingolipide bei der behandlung und prävention von hepatischer steatose

Country Status (6)

Country Link
US (1) US7906488B2 (de)
EP (1) EP1830829B1 (de)
JP (1) JP2008521888A (de)
AT (1) ATE539741T1 (de)
AU (1) AU2005310341A1 (de)
WO (1) WO2006059897A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10227290B2 (en) 2012-02-07 2019-03-12 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
US10329315B2 (en) 2012-10-12 2019-06-25 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
WO2015085121A1 (en) * 2013-12-05 2015-06-11 University Of Miami Compositions and methods for reducing intraocular pressure
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492259A1 (fr) 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
JPS61152632A (ja) 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
JPS6344842A (ja) 1986-08-12 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
EP0543922A4 (en) * 1990-08-13 1993-07-28 Duke University Methods for inducing cell differentiation using ceramides
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
FR2674748B1 (fr) 1991-04-03 1995-01-13 Oreal Utilisation de sphingolipides dans la preparation d'une composition cosmetique ou dermopharmaceutique protegeant la peau et les cheveux contre les effets nocifs de la pollution atmospherique.
US5232837A (en) * 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) * 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
US5714478A (en) 1995-09-29 1998-02-03 Spiegel; Sarah Sphingosylphosphorylcholine as a wound-healing agent
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
WO1997030174A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
CN1222293C (zh) 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α－糖基神经酰胺的NKT细胞活化剂
US6800661B1 (en) * 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6610835B1 (en) * 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
JP3581010B2 (ja) 1998-03-18 2004-10-27 雪印乳業株式会社 脂質の消化吸収機能改善剤
CA2329124A1 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
WO2000050574A1 (en) 1999-02-24 2000-08-31 Johns Hopkins University Compositions and methods for modulating serum cholesterol
JP3544493B2 (ja) 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
KR100341793B1 (ko) 1999-07-02 2002-06-24 권 영 근 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja) 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP2001158735A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 歯周病の予防及び改善剤
JP2001158736A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
WO2001060807A1 (en) 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1268414A1 (de) 2000-03-28 2003-01-02 The Liposome Company, Inc. Ceramid-derivate und verwendungsmethode
JP2002068998A (ja) * 2000-08-29 2002-03-08 Meiji Milk Prod Co Ltd 経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物
AU2001212597A1 (en) 2000-10-27 2002-05-06 N.V. Marc Boone Method for obtaining products enriched in phospho- and sphingolipids
US6949247B2 (en) * 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
FR2820037B1 (fr) 2001-01-29 2005-12-09 Dermaconcept Jmc Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2002226394A (ja) 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
ATE554779T1 (de) 2001-06-18 2012-05-15 Neptune Technologies & Bioressources Inc Krill zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
US8030348B2 (en) * 2001-07-27 2011-10-04 Neptune Technologies & Bioressources, Inc. Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
EP1291340B1 (de) 2001-09-05 2006-03-15 Charmzone Co., Ltd Phytosphingosinderivate mit Antitumorwirkung
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
DE10217555A1 (de) 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
AU2002349521A1 (en) 2002-08-14 2004-03-03 Tae-Yoon Kim A composition comprising phytospingosine derivatives for apoptosis induction
WO2004064820A2 (en) * 2003-01-20 2004-08-05 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0301395D0 (en) 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) * 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
EP1617808A4 (de) 2003-04-25 2011-11-02 Penn State Res Found Verfahren und system für die systemische abgabe von wachstumshemmenden von lipiden stammenden bioaktiven verbindungen

Also Published As

Publication number Publication date
WO2006059897A1 (en) 2006-06-08
EP1830829B1 (de) 2012-01-04
JP2008521888A (ja) 2008-06-26
EP1830829A1 (de) 2007-09-12
US7906488B2 (en) 2011-03-15
AU2005310341A1 (en) 2006-06-08
US20080182902A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
EP2065040A3 (de) Von Sphingolipiden abgeleitete pharmazeutische Zusammensetzungen
NZ707640A (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
JP2010522698A5 (de)
CA2792467A1 (en) Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
RU2018111327A (ru) Способ ингибирования всасывания и/или повышения выведения липидов с использованием d-псикозы
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
AR060974A1 (es) Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
EP2746254A3 (de) Oxadiazolderivat mit Wirkung auf Sphingosin-1-phosphat (s1p)
ATE539741T1 (de) Sphingolipide bei der behandlung und prävention von hepatischer steatose
MY168531A (en) Medicament form for release of active ingredients
WO2011065867A3 (en) Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
NZ589618A (en) PAEDIATRIC COMPOSITIONS COMPRISING 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol FOR TREATING MULTIPLE SCLEROSIS
GB2446341A (en) Method and system for transdermal drug delivery
JP2006516278A5 (de)
WO2018093237A3 (ko) 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
BRPI0715740A8 (pt) Agente redutor de triglicerídeos séricos
MX2007009985A (es) Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos.